GILD Gilead Sciences, Inc. Stock Quote

GILD [NASD]

Healthcare | Drug Manufacturers - General | USA

Index	S&P 500	P/E	18.81	EPS (ttm)	3.28	Insider Own	0.09%	Shs Outstand	1.26B	Perf Week	-1.86%
Market Cap	78.44B	Forward P/E	9.53	EPS next Y	6.47	Insider Trans	0.00%	Shs Float	1.25B	Perf Month	-2.80%
Income	4.14B	PEG	-	EPS next Q	1.55	Inst Own	82.60%	Short Float	1.33%	Perf Quarter	-1.07%
Sales	27.52B	P/S	2.85	EPS this Y	-8.80%	Inst Trans	0.68%	Short Ratio	2.47	Perf Half Y	3.77%
Book/sh	16.11	P/B	3.83	EPS next Y	-2.60%	ROA	6.30%	Target Price	70.78	Perf Year	-11.68%
Cash/sh	4.45	P/C	13.85	EPS next 5Y	-1.23%	ROE	20.00%	52W Range	57.17 - 74.12	Perf YTD	-15.04%
Dividend	2.92	P/FCF	13.63	EPS past 5Y	-13.10%	ROI	16.40%	52W High	-16.77%	Beta	0.32
Dividend %	4.73%	Quick Ratio	1.30	Sales past 5Y	-2.10%	Gross Margin	75.60%	52W Low	7.92%	ATR	1.48
Employees	14400	Current Ratio	1.40	Sales Q/Q	0.70%	Oper. Margin	25.50%	RSI (14)	40.66	Volatility	2.36% 2.25%
Optionable	Yes	Debt/Eq	1.30	EPS Q/Q	-24.80%	Profit Margin	15.00%	Rel Volume	1.30	Prev Close	63.07
Shortable	Yes	LT Debt/Eq	1.25	Earnings	Aug 02 AMC	Payout	87.40%	Avg Volume	6.76M	Price	61.69
Recom	2.60	SMA20	-4.26%	SMA50	-2.53%	SMA200	-2.98%	Volume	8,788,797	Change	-2.19%

Jul-13-22

Initiated

Cantor Fitzgerald

Neutral

$70

May-23-22

Initiated

SVB Leerink

Mkt Perform

$68

Feb-28-22

Downgrade

BMO Capital Markets

Outperform → Market Perform

$75 → $65

Feb-02-22

Reiterated

Wells Fargo

Equal Weight

$72 → $70

Feb-02-22

Reiterated

Truist

Hold

$77 → $75

Feb-02-22

Reiterated

RBC Capital Mkts

Outperform

$87 → $85

Feb-02-22

Reiterated

BofA Securities

Neutral

$73 → $71

Feb-02-22

Reiterated

BMO Capital Markets

Outperform

$85 → $75

Jan-28-22

Upgrade

Argus

Hold → Buy

Jan-06-22

Downgrade

Morgan Stanley

Overweight → Equal-Weight

$84 → $74

Dec-09-21

Resumed

Wells Fargo

Equal Weight

$72

Dec-06-21

Initiated

Goldman

Neutral

$80

Nov-19-21

Upgrade

BMO Capital Markets

Market Perform → Outperform

$72 → $85

Nov-19-21

Resumed

Piper Sandler

Neutral

$77

Oct-20-21

Resumed

Cowen

Outperform

Jul-30-21

Reiterated

RBC Capital Mkts

Outperform

$81 → $84

Jul-30-21

Reiterated

BMO Capital Markets

Market Perform

$67 → $72

Apr-01-21

Upgrade

Bernstein

Mkt Perform → Outperform

$80

Mar-30-21

Upgrade

Redburn

Neutral → Buy

Jan-19-21

Upgrade

Morgan Stanley

Equal-Weight → Overweight

$83

Sep-30-22 09:55AM	Gilead Sciences: Mother of Three Shares Her CAR T-Cell Therapy Journey: Kelly's Story ACCESSWIRE
Sep-29-22 07:10AM	Gilead's Investigation Reveals Two Kingpins Directly Associated With Fake HIV Medications Scheme Benzinga
Sep-28-22 08:12PM	Gilead widens battle against alleged counterfeit HIV drug ring Reuters
08:00PM	Gilead widens battle against alleged counterfeit HIV drug ring Reuters
01:00PM	Gilead Sciences: WHO Expands Recommendation for Veklury(R) (Remdesivir) to Patients With Severe Disease in Latest Update to COVID-19 Guideline ACCESSWIRE
09:02AM	Loading…
09:02AM	In the wake of Gilead Sciences, Inc.'s (NASDAQ:GILD) latest US$2.4b market cap drop, institutional owners may be forced to take severe actions Simply Wall St.
Sep-27-22 05:50PM	Gilead Sciences (GILD) Gains As Market Dips: What You Should Know Zacks
Sep-24-22 09:00AM	Institutional owners may take dramatic actions as Gilead Sciences, Inc.'s (NASDAQ:GILD) recent 4.2% drop adds to one-year losses Simply Wall St.
Sep-23-22 10:10AM	4 Questions With Dr. Javier Cortes: The Importance of Scientific Exchange To Advance Breast Cancer ACCESSWIRE
09:45AM	Got $1,000? 2 Stocks That Could Be Bargain Buys For 2022 and Beyond Motley Fool
Sep-22-22 12:17PM	Biotech Stock Roundup: GILD, BMY's Regulatory News, BLUE's Therapy Approval & More Zacks
08:30AM	Gilead Joins First-of-its-Kind Public-Private Initiative to Improve Management of Viral Hepatitis in Vietnam and the Philippines Business Wire
Sep-21-22 05:50PM	Gilead Sciences (GILD) Stock Moves -1.67%: What You Should Know Zacks
01:49PM	Quant Billionaire Jim Simons Loves These 10 Defensive Stocks Insider Monkey
Sep-20-22 04:30PM	Gilead Sciences Completes Acquisition of MiroBio Business Wire
08:02AM	Loading…
08:02AM	Gilead Sciences, Inc.'s (NASDAQ:GILD) latest 3.2% decline adds to one-year losses, institutional investors may consider drastic measures Simply Wall St.
Sep-19-22 09:28AM	Gilead (GILD) Drugs Get Positive CHMP Opinion for Label Expansion Zacks
Sep-16-22 02:58PM	WHO Recommends Gilead's (GILD) Veklury for Severe COVID-19 Zacks
07:04AM	WHO Recommends Gilead's COVID-19 Therapy For Severe Disease Benzinga
07:00AM	Kites CAR T-cell Therapy Yescarta® First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma Business Wire
06:56AM	EU regulator recommends extending Gilead's COVID treatment Veklury for use in pediatric patients MarketWatch
06:39AM	CHMP Adopts Positive Opinion to Extend Indication of Veklury® (Remdesivir) for the Treatment of Pediatric Patients with COVID-19 Business Wire
Sep-15-22 06:48PM	Gilead COVID-19 drug gets expanded WHO recommendation MarketWatch
06:21PM	WHO Expands Recommendation for Veklury® (Remdesivir) to Patients With Severe Disease in Latest Update to COVID-19 Guideline Business Wire
05:50PM	Gilead Sciences (GILD) Stock Moves -0.28%: What You Should Know Zacks
01:30PM	Delayed Generic Entry Is Positive For This Large Pharma's HIV Franchise Sales, Analyst Says Benzinga
09:55AM	Mentoring Mothers Living With HIV: Angelina's Story News Direct
Sep-14-22 05:52AM	My Biggest Worry About Gilead Sciences Motley Fool
Sep-13-22 05:44PM	Gilead (GILD) Up on Settling HIV Drug Suit With Generic Players Zacks
11:28AM	Gilead Foundation Awards $20 Million to Organizations Working to Advance Health Through Education Equity Business Wire
10:48AM	Loading…
10:48AM	Should Investors Buy a Pullback in Gilead Sciences? TheStreet.com
09:32AM	Company News for Sep 13, 2022 Zacks
05:25AM	3 Unstoppable Dividend Stocks to Buy in September Motley Fool
Sep-12-22 09:08AM	Gilead's stock jumps 5% after setting patent case related to HIV therapies MarketWatch
Sep-10-22 02:37PM	Top 10 Stock Picks of John Zaros Bourgeon Capital Insider Monkey
08:39AM	Is It Worth Considering Gilead Sciences, Inc. (NASDAQ:GILD) For Its Upcoming Dividend? Simply Wall St.
Sep-09-22 05:45PM	Gilead Sciences (GILD) Gains But Lags Market: What You Should Know Zacks
11:15AM	Gilead Sciences Stock Sees Relative Strength Rating Jump To 84 Investor's Business Daily
Sep-08-22 05:50PM	Gilead Sciences (GILD) Gains But Lags Market: What You Should Know Zacks
01:27PM	Gilead's Trodelvy Shows Improved Overall Survival In Pretreated Breast Cancer Settings Benzinga
11:53AM	Gilead (GILD) Breast Cancer Drug Trodelvy Improves Survival Zacks
Sep-07-22 06:05PM	Trodelvy® Significantly Improved Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in TROPiCS-02 Study Business Wire
06:05PM	Gilead's Trodelvy extends breast cancer survival by 3.2 months -study Reuters
01:15PM	Gilead's (GILD) Tecartus Gets EC Nod for New Cancer Indication Zacks
12:37PM	Biotech Stock Roundup: GILD's Updates, FMTX Up on NVO Deal, SPRO Surges & More Zacks
11:30AM	Clovis (CLVS) Down 12.6% Since Last Earnings Report: Can It Rebound? Zacks
08:45AM	Overcoming Blood Cancer With CAR T-cell Therapy: Eleonora's Journey News Direct
Sep-06-22 06:30PM	Kites CAR T-cell Therapy Tecartus® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL) Business Wire
03:05PM	Gilead's Breast Cancer Drug Improves Progression-Free Survival in HR+/HER2- Metastatic Breast Cancer Benzinga
10:16AM	Gilead (GILD) Announces Positive New Data on Breast Cancer Drug Zacks
Sep-04-22 06:05PM	New TROPiCS-02 Data in HR+/HER2- Metastatic Breast Cancer Patients Demonstrates Progression-Free Survival Benefit of Trodelvy® Regardless of Their HER2 Status Business Wire
Sep-03-22 06:08AM	3 Great Dividend Stocks to Buy in September Motley Fool
Sep-02-22 05:45PM	Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know Zacks
11:31AM	Horizon Therapeutics (HZNP) Down 9.2% Since Last Earnings Report: Can It Rebound? Zacks
Sep-01-22 11:31AM	Gilead (GILD) Up 1.9% Since Last Earnings Report: Can It Continue? Zacks
Aug-31-22 09:00AM	4 Questions With Jared Baeten: Innovating, Collaborating and Inspiring at Aids 2022 News Direct
Aug-30-22 11:51AM	Gilead (GILD) Outpaces Industry in Six Months: What Lies Ahead? Zacks
Aug-29-22 04:05PM	Gilead Sciences to Present at Upcoming Investor Conferences Business Wire
08:30AM	Gilead Demonstrates Strength of Oncology Portfolio Across Diverse Tumor Types at ESMO Congress 2022 Business Wire
Aug-25-22 10:23AM	Want $1,100 in Passive Income? Invest $20,000 in These 2 Stocks Motley Fool
Aug-24-22 09:57AM	Biotech Stock Roundup: GILD, BLUE, AXSM's Drug Approvals, FHTX Study Update & More Zacks
Aug-22-22 11:57AM	Gilead (GILD) Twice-Yearly HIV Treatment Gets EC Approval Zacks
01:00AM	Gilead Announces First Global Regulatory Approval of Sunlenca® (Lenacapavir), the Only Twice-Yearly HIV Treatment Option Business Wire
Aug-19-22 08:45AM	Ashley Innes Relishes Opportunity to Make Her Mark on HIV Epidemic in Southern U.S. News Direct
Aug-18-22 09:55AM	Gilead Sciences Announces Collaboration With Morehouse School of Medicine and Xavier University of Louisiana College of Pharmacy To Address Inequities in HIV Care News Direct
Aug-17-22 12:15PM	Biotech Stock Roundup: GILD's Drug News, NVAX & MRNA COVID-19 Vaccine Updates Zacks
11:00AM	Gilead Sciences Announces Collaboration With Morehouse School of Medicine and Xavier University of Louisiana College of Pharmacy to Address Inequities in HIV Care Business Wire
Aug-16-22 01:10PM	Gilead (GILD) Announces Positive Data on Breast Cancer Drug Zacks
12:08PM	Gilead Data on Breast Cancer Drug Is Surprise Win, Analyst Says Barrons.com
08:45AM	Gilead Sciences and a Coalition of LGBTQ+ and Human Rights-Focused Organizations Mobilize to Address Monkeypox Public Health Emergency News Direct
Aug-15-22 07:15PM	Gilead to Acquire Remaining Worldwide Rights of Trodelvy® Business Wire +5.16%
05:29PM	Why Gilead Sciences Stock Was a 5% Winner Today Motley Fool
04:42PM	IBD Stock Of The Day AstraZeneca Stalls As Gilead Looks To Take Its Breast Cancer Market Investor's Business Daily
04:28PM	Nasdaq 100 surges ahead of this week's retail earnings Yahoo Finance Video
03:06PM	Gilead's stock is up about 4% after sharing new data for cancer drug MarketWatch
10:20AM	Stocks gaining in early trading: Nvidia, AMD, Tesla, Moderna, Gilead Yahoo Finance Video
08:30AM	Trodelvy® Significantly Improves Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in the TROPiCS-02 Study Business Wire
Aug-11-22 08:45AM	Gilead's Hackathon Unearths Innovative Ways To Improve HIV Prevention News Direct
Aug-10-22 05:13AM	3 Healthcare Stocks With High Profit Margins Motley Fool
Aug-09-22 10:00AM	Gilead Sciences and a Coalition of LGBTQ+ and Human Rights-Focused Organizations Mobilize to Address Monkeypox Public Health Emergency Business Wire
09:45AM	Drugmaker Gilead to help fund monkeypox education for LGBTQ+ groups Reuters
07:50AM	Gilead Sciences (GILD) Gained from its HIV and COVID-19 Drugs Insider Monkey
Aug-07-22 10:45AM	2 Reasons This Beaten-Down Stock Could Be About to Rebound Motley Fool
Aug-04-22 12:13PM	Gilead Sciences Bets $400M On Inflammatory Diseases Focused UK Based Firm Benzinga
09:55AM	A Diverse Workforce Enables Businesses to Succeed News Direct
09:31AM	What Kind Of Investors Own Most Of Gilead Sciences, Inc. (NASDAQ:GILD)? Simply Wall St.
08:00AM	Gilead Sciences to Acquire MiroBio Business Wire
Aug-03-22 05:40PM	Senate Democrats just proposed $21 billion in new COVID-19 funding here are 3 healthcare stocks that could stand to gain MoneyWise
04:04PM	Gilead Boosts 2022 Guidance On The Back Of Its Covid Treatment Investor's Business Daily
03:46PM	Top 10 Gainers on Wednesday Insider Monkey
12:12PM	Stock Market Today: Dow Delivers Swashbuckling Gains as Earnings Shine Investing.com
11:51AM	Why Gilead Sciences Stock Is Jumping Today Motley Fool
10:58AM	S&P 500 in Rally Mode on Positive Earnings, Stronger Economic Data Investing.com
09:53AM	Gilead (GILD) Q2 Earnings & Sales Top, Revenue Outlook Upped Zacks
06:14AM	Gilead Sciences' Q2 Beats Street View On Robust Oncology, HIV Product Sales Benzinga
Aug-02-22 11:00PM	Gilead Sciences (GILD) Q2 2022 Earnings Call Transcript Motley Fool
05:25PM	Gilead Sciences (GILD) Beats Q2 Earnings and Revenue Estimates Zacks
04:34PM	Gilead Sciences tweaks fiscal-year outlook following Q2 results MarketWatch
04:01PM	Gilead Sciences Announces Second Quarter 2022 Financial Results Business Wire
Aug-01-22 01:59PM	Drug, Biotech Stocks' Q2 Earnings on Aug 2: GILD, INCY & More Zacks

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lofton Kevin E	Director	Apr 28	Option Exercise	25.62	16,322	418,251	90,525	Apr 29 06:43 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Mar 11	Sale	58.24	3,634	211,644	32,576	Mar 14 09:46 PM
Mercier Johanna	Chief Commercial Officer	Mar 10	Option Exercise	0.00	6,987	0	37,765	Mar 14 09:14 PM
O'Day Daniel Patrick	Chairman & CEO	Mar 10	Option Exercise	0.00	24,003	0	260,396	Mar 14 09:52 PM
Wilfong Diane E.	SVP, Controller & CAO	Mar 10	Option Exercise	0.00	3,297	0	27,516	Mar 14 09:30 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Feb 09	Sale	63.89	1,691	108,038	32,576	Feb 11 02:57 PM
Dickinson Andrew D	Chief Financial Officer	Feb 06	Option Exercise	0.00	1,817	0	60,473	Feb 08 08:25 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Feb 06	Option Exercise	0.00	2,727	0	35,303	Feb 08 08:24 PM
Wilfong Diane E.	SVP, Controller & CAO	Feb 06	Option Exercise	0.00	1,864	0	24,739	Feb 08 08:22 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Feb 01	Sale	68.54	14,061	963,682	32,576	Feb 02 06:37 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience